At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 07:22 ET
Foghorn Therapeutics reported Q3 2026 net income of $58.2M, driven by a $74.1M cumulative catch-up adjustment in collaboration revenue from the decision to not advance two partnered programs. The company has $156.2M in cash with runway into H2 2029, but the core business remains pre-revenue and the reported profit is non-recurring. Consensus estimates were not met on an operating basis.
- Net income of $58.2M vs net loss of $15.8M in Q3 2025, driven by $74.1M cumulative catch-up adjustment in collaboration revenue
- Collaboration revenue of $83.5M vs $8.2M in Q3 2025, primarily from the catch-up adjustment
- Cash, cash equivalents and marketable securities of $156.2M, providing runway into H2 2029
- R&D expenses decreased to $18.8M from $20.0M; G&A expenses decreased to $5.8M from $6.7M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access